# An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease

> **NCT04514367** · PHASE2 · COMPLETED · sponsor: **Annexon, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** ANX005

## Key facts

- **NCT ID:** NCT04514367
- **Lead sponsor:** Annexon, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-17
- **Primary completion:** 2022-01-28
- **Final completion:** 2022-01-28
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04514367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04514367, "An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04514367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*